What is claimed:

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is selected from the group consisting of H or methyl; and

R_2 is selected from the group consisting of H or methyl.

2. The compound as recited in claim 1 wherein:

R_1 is H; and

R_2 is selected from the group consisting of H or methyl.

3. The compound as recited in claim 1 wherein:

R_1 is H; and

R_2 is H.

4. The compound as recited in claim 1 wherein:

R_1 is H; and

R_2 is methyl.

5. The compound as recited in claim 1 wherein:

R_1 is methyl; and

R_2 is hydrogen or methyl.

6. The compound as recited in claim 1 wherein:

R_1 is methyl; and

R_2 is H.

7. The compound as recited in claim 1 wherein:

R_1 is methyl; and

R_2 is methyl.

8. The compound as recited in claim 1 wherein:

R_1 is selected from the group consisting of H or methyl; and

R_2 is H.

9. The compound as recited in claim 1 corresponding to Formula II



II

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is selected from the group consisting of H and methyl; and

R_2 is selected from the group consisting of H and methyl.

10. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is selected from the group consisting of H and methyl.

11. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is H.

12. The compound as recited in claim 9 wherein:

R_1 is H; and

R_2 is methyl.

13. The compound as recited in claim 9 wherein:

R_1 is methyl; and

R_2 is selected from the group consisting of H and methyl.

14. The compound as recited in claim 9 wherein:

R_1 is methyl; and

R_2 is H.

15. The compound as recited in claim 9 wherein:

R_1 is methyl; and

R_2 is methyl.

16. The compound as recited in claim 9 wherein:

R_1 is selected from the group consisting of H and methyl; and

R_2 is H.

17. The compound as recited in claim 1 corresponding to Formula III:



III

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is selected from the group consisting of H and methyl; and

R_2 is selected from the group consisting of H and methyl.

18. The compound as recited in claim 17 wherein:

R_1 is H; and

R_2 is selected from the group consisting of H and methyl.

19. The compound as recited in claim 17 wherein:

R_1 is H; and

R_2 is H.

20. The compound as recited in claim 17 wherein:

R_1 is H; and

R_2 is methyl.

21. The compound as recited in claim 17 wherein:

R_1 is methyl; and

R_2 is selected from the group consisting of H and methyl.

22. The compound as recited in claim 17 wherein:

R_1 is methyl; and

R_2 is H.

23. The compound as recited in claim 17 wherein:

R_1 is methyl; and

R_2 is methyl.

24. The compound as recited in claim 17 wherein:

R_1 is selected from the group consisting of H and methyl; and

R_2 is H.

25. A compound as recited in claim 1 wherein the compound is the S enantiomer.

25 A compound as recited in claim 1 wherein the compound is the R enantiomer.

26 A compound as recited in claim 1 wherein the compound is the E isomer.

27. A compound as recited in claim 1 wherein the compound is the Z isomer.

28. A compound selected from the group consisting of:

(2S, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4Z)-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;

(2 R/S, 4E)-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2 R/S, 4Z)-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4E)-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4Z)-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4E)-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2S, 4Z)-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;

(2R, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid; and

(2R, 4Z)-Amino-6-(1-iminoethylamino)-hept-4-enoic acid.

29. A pharmaceutical composition comprising a compound of claim 1.

30 A method of inhibiting nitric oxide synthesis in a subject in need of such inhibition by administering a therapeutically effective amount of a compound of claim 1.

31. The method as recited in claim 30 wherein said nitric oxide synthase is an inducible nitric oxide synthase isoform, said inhibition selective for inducible nitric oxide synthase over the constitutive forms of nitric oxide synthase in a subject in need of such inhibition.